arrow
A

Alain Delmer

assistance publique hopitaux paris (aphp)
H指数:56
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

克唑替尼治疗儿童、青少年和成年患者ALK阳性系统性间变性大细胞淋巴瘤的疗效和安全性: 法国acsé-crizotinib试验结果

2023-09-0110
OAAI
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
2023-07-274
OAAI
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
2023-01-1917
OAAI
Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
2022-12-224
OAAI
High frequency of central nervous system involvement in transformed Waldenstrom macroglobulinemia
2022-06-215
OAAI
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
2022-01-0740
OAAI
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)
2021-07-011
OAAI
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort
2021-01-2526
PREAI
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
2021-01-2251
OA
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
LEUKEMIA
IF13.4
2021-01-2216
PREAI
A prognostic index predicting survival in transformed Waldenstrom macroglobulinemia
2020-11-1214
OAAI
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
2020-09-2325
OAAI
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed of Refractory Hodgkin Lymphoma
RADIOLOGY
IF15.2
2020-06-0125
PREAI
Impact of MYD88L265P mutation status on histological transformation of Waldenstrom Macroglobulinemia
2019-12-3140
OAAI
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

早期18F-FDG PET/CT反应可预测Nivolumab治疗复发或难治性霍奇金淋巴瘤的生存率

2019-10-1839
OAAI
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
2019-09-0120
OAAI